No profile data available.
MoonLake Immunotherapeutics (MLTX) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Zug, Switzerland, with about 130 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$227.32 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $920.85 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases.
MoonLake Immunotherapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$920.85 million as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Oculis Holding AG (OCS), Amphastar Pharmaceuticals, Inc. (AMPH), MannKind Corporation (MNKD), Jade Biosciences, Inc. (JBIO).